Why GSK and Sanofi Shares are Trading Sharply Lower This Week
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to Why GSK and Sanofi Shares are Trading Sharply Lower This Week
August 11, 2022 3:43 PM EDT
In response to recent speculative commentary regarding U.S. Zantac litigation, GSK plc (LSE/NYSE: GSK) today issued the following statement regarding Zantac (ranitidine) and N-nitrosodimethylamine (NDMA).
There have been no material developments to what has been previously disclosed.
GSK, independent cancer researchers, the U.S. Food & Drug Administration, and the European Medicines Agency, have all undertaken extensive reviews of available data and conducted numerous investigations into this issue since 2019.
Based on these investigations and experiments, GSK, the FDA, and the EMA have all independently concluded that there is no... More
August 11, 2022 7:27 AM EDT
By Natalie Grover and Danilo Masoni
LONDON (Reuters) -Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.
GSK shares fell more than 10%, Sanofi's stock sagged about 3.3% and Haleon's shares slipped nearly 5% at the close of trading on Thursday.
GSK, the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA) have all concluded after experiments that there is no evidence of a causal association between therapy with the heartburn drug... More
August 11, 2022 7:13 AM EDT
Sanofi (NASDAQ: SNY), GSK (NYSE: GSK) Lead $40 Billion Rout as Zantac Worries Mount - Bloomberg
Sanofi has lost 20% on litigation worries
...
More
